載入中
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
前收盤價
US$3.46
−US$0.01 · -0.29%
盤中時間採用ET。市場資料可能有所延遲。
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
日內區間
目前US$3.46
52週區間
目前US$3.46
盤中時間採用ET。市場資料可能有所延遲。
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
日內區間
目前US$3.46
52週區間
目前US$3.46
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4272.7萬 USD | 1.08億 USD | 1.13億 USD | 364.9萬 USD | 4096.4萬 USD |
| 銷貨成本 | 885.2萬 USD | — | — | — | — |
| 毛利 | 3387.5萬 USD | 1.08億 USD | 1.13億 USD | 364.9萬 USD | 4096.4萬 USD |
| 研究與開發 | 1.83億 USD | 1.6億 USD | 1.3億 USD | 1.16億 USD | 1.22億 USD |
| 銷售、一般及管理費用 | 7533.1萬 USD | 5902.3萬 USD | 5129.2萬 USD | 5051.3萬 USD | 4610.5萬 USD |
| 營業費用 | 2.49億 USD | 2.19億 USD | 1.81億 USD | 1.66億 USD | 1.68億 USD |
| 利息收入 | 1047.8萬 USD | — | — | — | 3萬 USD |
| 折舊和攤銷 | 885.2萬 USD | 866.3萬 USD | 920.6萬 USD | 1011.4萬 USD | 983.5萬 USD |
| 營業利益 | −2.15億 USD | −1.1億 USD | −6799.6萬 USD | −1.63億 USD | −1.27億 USD |
| 淨利 | −2.04億 USD | −9700.8萬 USD | −5751.3萬 USD | −1.62億 USD | −1.22億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM1276.05萬0.02%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF868.43萬0.01%954億 USD0.05%US$235+0.80%
State Street SPDR S&P Pharmaceuticals ETFXPH605.18萬1.31%4.62億 USD0.35%US$64.65+1.60%
iShares Biotechnology ETFIBB434.95萬0.04%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO388.6萬0.02%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA272.32萬0.01%218.24億 USD0.03%US$32.79+0.40%
Dimensional - US Small Cap ETFDFAS266.46萬0.01%338.69億 USD0.31%US$78.35+0.32%
Vanguard Health Care ETFVHT193.87萬0.01%220億 USD0.09%US$319.01+1.64%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHADimensional - US Small Cap ETFDFASVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
